Covenant Therapeutics LLC
Charlottesville, VA
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- SAM.gov registration date
- Physical address
- 1812 Warbler Way, Charlottesville, VA 22903, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract subawards
| Prime contractor | Prime award | Amount | Awarded |
|---|---|---|---|
| George Mason University | HT942523C0099 | $186,428 |
Grant awards
Similar vendors
About the company
Covenant Therapeutics LLC is a biomedical research company specializing in the development of novel therapeutic approaches for various medical conditions. Registered with the federal government since 2010, the company is structured as a partnership or limited liability partnership and is classified as a minority-owned, Asian-Pacific American owned small business. Covenant Therapeutics focuses on creating innovative drug candidates and therapeutic solutions, particularly in the areas of cardiovascular and pulmonary diseases.
While no specific information about federal contract awards is provided in the given data, Covenant Therapeutics LLC has participated in federal contracting as a subcontractor. The company has been involved in a subcontract under prime contractor George Mason University, working on a project to develop new antibiotic compounds. This three-year project involves synthesizing libraries of compounds to establish a structure-activity relationship for peptide derivatives of CT-AP1, a compound with antibiotic activity. The work includes developing second-generation analogs with improved activity and producing large quantities of lead compounds for in vivo studies.
Covenant Therapeutics LLC has received federal grant awards from the National Heart Lung and Blood Institute (NHLBI) to support its research and development efforts. One notable project grant (R43HL167440) focuses on designing safe, potent, and cost-effective small peptide erythropoietin analogs as an alternative to recombinant human erythropoietin (rHuEPO) for anemia treatment. This research aims to create a more affordable, safer, and conveniently administered therapeutic option for patients with anemias secondary to renal disease and malignancy. Another grant (R43HL154868) supported the development of a novel class therapy for idiopathic pulmonary fibrosis (IPF). These grants demonstrate Covenant Therapeutics' commitment to advancing cardiovascular and pulmonary medicine through innovative approaches to drug development and therapeutic interventions.
Quick answers
Is Covenant Therapeutics LLC registered in SAM.gov?
Yes. Covenant Therapeutics LLC's SAM.gov registration is active through December 4, 2026.
What is Covenant Therapeutics LLC's CAGE code?
Covenant Therapeutics LLC's CAGE code is 66GD9, and its Unique Entity ID (UEI) is KKJLPNVZZWT2.
What is Covenant Therapeutics LLC's most recent federal award?
Covenant Therapeutics LLC's most recent federal grant award is Designing safe, potent, and cost-effective small peptide erythropoietin analogs - recombinant human erythropoietin… (R43HL167440), from National Heart Lung and Blood Institute (NIH), on September 10, 2023.
On GovTribe
See Covenant Therapeutics LLC's full federal record
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors